U.S. markets closed
  • S&P Futures

    4,465.25
    +36.25 (+0.82%)
     
  • Dow Futures

    35,191.00
    +407.00 (+1.17%)
     
  • Nasdaq Futures

    15,144.25
    +107.00 (+0.71%)
     
  • Russell 2000 Futures

    2,264.10
    -8.00 (-0.35%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    16.30
    -0.56 (-3.32%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    61,265.54
    +414.23 (+0.68%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

ObsEva's Menstrual Bleeding Drug Produces 'Best-In-Class' Response In Late-Stage Study

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Swiss biopharma Obseva SA (NASDAQ: OBSV), which is developing orally administered, clinical-stage compounds to treat women's reproductive health conditions, announced a positive late-stage clinical readout Monday for its investigational compound to treat heavy menstrual bleeding due to uterine fibroids.

ObsEva saw its shares a decline steeply in early November due to a failed trial of nolasiban, another pipeline asset.

ObsEva's Study Results

The Phase 3 study dubbed PRIMROSE 2 met the primary and secondary efficacy endpoints, ObsEva said.

The study evaluated once-daily oral linzagolix in 100mg and 200mg doses, with and without hormonal add-back therapy, or ABT,

The primary efficacy endpoint was the reduction in heavy menstrual bleeding.

The responder rate was 93.9% for women receiving 200mg linzagolix with ABT and 56.7% for women receiving 100mg without ABT versus 29.4% for the placebo group. The company termed the response for the 200mg dose as "best-in-class."

Both doses achieved significant rates of amenorrhea, reduction in pain and improvement in quality of life, according to ObsEva.

Linzagolix also led to significant improvement in hemoglobin levels, a reduction in the number of days of bleeding and a reduction in uterine volume, the company said.

ObsEva noted a significant reduction in fibroid volume for the 200mg dose with ABT.

The safety profile was in-line with expectations, confirming that linzagolix was well-tolerated.

See Also: 12 Biotech Stocks Primed For A Short Squeeze

Why Linzagolix Data Is Important

Linzagolix is a GnRH antagonist that is being developed in late-stage studies for endometriosis and uterine fibroids.

ObsEva licensed the compound from the Japanese biotech Kissei in late 2015.

A dire need exists for non-surgical alternatives for uterine fibroids to reduce the effects of heavy menstrual bleeding.

"The prospects for a medical treatment with multiple dosing options would address a need for this diverse population of women. I am particularly impressed with the 94% responder rate and 80% amenorrhea rate that linzagolix has shown," Dr. Hugh Taylor, chair of obstetrics and gynecology at the Yale University, said in a statement.

The 50% response shown by patients taking the 100mg dose without ABT provides a meaningful option for women who cannot or do not want to take exogenous hormones.

ObsEva said it expects results form the Phase 3 PRIMROZSE 1 study conducted in the U.S. in the second quarter of 2020.

Provided the study also ends with positive results, the company plans to submit a Marketing Authorization Application in Europe by the end of 2020 and a New Drug Application in the U.S. by the first quarter of 2021.

ObsEva shares were down 13.79% at $3.94 at the time of publication Monday.

0

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.